T C Theoharides

Summary

Affiliation: Tufts University
Country: USA

Publications

  1. ncbi Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation
    W Boucher
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    J Urol 177:1186-90. 2007
  2. ncbi Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects
    T C Theoharides
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Endocrinology 139:403-13. 1998
  3. ncbi Interstitial cystitis: a neuroimmunoendocrine disorder
    T C Theoharides
    Department of Pharmacology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Ann N Y Acad Sci 840:619-34. 1998
  4. ncbi Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells
    P Esposito
    Departments of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Brain Res 888:117-127. 2001
  5. ncbi Acute stress and intravesical corticotropin-releasing hormone induces mast cell dependent vascular endothelial growth factor release from mouse bladder explants
    J Cao
    Department of Biochemistry, Tufts University School of Medicine, Tufts-New England Medical Center, 136 Harrison Avenue, Boston, MA 02111, USA
    J Urol 176:1208-13. 2006
  6. ncbi Chondroitin sulphate inhibits connective tissue mast cells
    T C Theoharides
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, Massachusetts, MA 02111, USA
    Br J Pharmacol 131:1039-49. 2000
  7. ncbi Intravesical nanocrystalline silver decreases experimental bladder inflammation
    W Boucher
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    J Urol 179:1598-602. 2008
  8. ncbi Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek--an oral multi-agent natural supplement
    T C Theoharides
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts 02111, USA
    Can J Urol 15:4410-4. 2008
  9. ncbi Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells
    M Vasiadi
    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Br J Dermatol 166:1349-52. 2012
  10. ncbi Urticaria pigmentosa associated with acute stress and lesional skin mast-cell expression of CRF-R1
    T C Theoharides
    Department of Pharmacology, Tufts University School of Medicine, Tufts Medical Center, Boston, MA 02111, USA
    Clin Exp Dermatol 34:e163-6. 2009

Collaborators

  • D Kempuraj
  • G R Sant
  • B Zhang
  • P Conti
  • J Cao
  • A J Stratigos
  • M Makris
  • E M Messing
  • I Correia
  • Y Wang
  • S Basu
  • M L Castellani
  • J M Stern
  • K Peters
  • P M Hanno
  • L Hesse
  • Le Xin Wang
  • W Boucher
  • D Kalogeromitros
  • M Vasiadi
  • D Papaliodis
  • R Letourneau
  • P Esposito
  • N Sismanopoulos
  • A Miniati
  • K D Alysandratos
  • Z Weng
  • M Green
  • S Asadi
  • A Katsarou-Katsari
  • K Bhattacharya
  • S Jacobson
  • L Speranza
  • R Connolly
  • L Logothetis
  • D V Avgerinos
  • M Huang
  • M G Alexandrakis
  • W S Boucher
  • N Chandler
  • D Mavrommati
  • E Hatziagelaki
  • D A Delivanis
  • C Antoniou
  • A Therianou
  • E Papadavid
  • E Nicolaidou
  • D Gheorghe
  • J J Rozniecki
  • A Theoharides
  • U Reuter
  • T Petrakopoulou
  • N Stavrianeas
  • A Angelidou
  • C Chliva
  • V Kotsinyan
  • K Olness
  • X Aggelides
  • M S Cohen
  • K Farwell
  • S Tete
  • A Patruno
  • A Grilli
  • B Madhappan
  • M A De Lutiis
  • J Donelan
  • J Vecchiet
  • F Mastrangelo
  • F Conti
  • Y B Shaik
  • A Tetè
  • M Felaco
  • A Zafeiropoulos
  • S Gregoriou
  • A Orologas
  • I A Mylonas
  • M Pashalidou
  • S Baloyannis
  • V Kosta
  • A Filippou
  • D Seretakis
  • V Dimitriadou
  • D S Kyriakou
  • M A Moskowitz
  • X Pang
  • K Kandere
  • C Waeber
  • M Sanchez del Rio
  • I Jansen-Olesen
  • H Bolay

Detail Information

Publications45

  1. ncbi Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation
    W Boucher
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    J Urol 177:1186-90. 2007
    ..We investigated the effect of intravesical IPD-1151T on mediator release from bladder explants in experimental cystitis...
  2. ncbi Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects
    T C Theoharides
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Endocrinology 139:403-13. 1998
    ..The present results have implications for the pathophysiology and possible therapy of skin disorders, such as atopic dermatitis, eczema, psoriasis, and urticaria, which are exacerbated or precipitated by stress...
  3. ncbi Interstitial cystitis: a neuroimmunoendocrine disorder
    T C Theoharides
    Department of Pharmacology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Ann N Y Acad Sci 840:619-34. 1998
    ..These findings suggest that IC could be a syndrome with neural, immune, and endocrine components, in which activated mast cells play a central role...
  4. ncbi Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells
    P Esposito
    Departments of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Brain Res 888:117-127. 2001
    ..These results expand the pathophysiology of mast cells and implicate them in CNS disorders, that may possibly be induced or exacerbated by stress...
  5. ncbi Acute stress and intravesical corticotropin-releasing hormone induces mast cell dependent vascular endothelial growth factor release from mouse bladder explants
    J Cao
    Department of Biochemistry, Tufts University School of Medicine, Tufts-New England Medical Center, 136 Harrison Avenue, Boston, MA 02111, USA
    J Urol 176:1208-13. 2006
    ....
  6. ncbi Chondroitin sulphate inhibits connective tissue mast cells
    T C Theoharides
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, Massachusetts, MA 02111, USA
    Br J Pharmacol 131:1039-49. 2000
    ..5. Chondroitin sulphate appears to be a potent mast cell inhibitor of allergic and nonimmune stimulation with potential clinical implications...
  7. ncbi Intravesical nanocrystalline silver decreases experimental bladder inflammation
    W Boucher
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    J Urol 179:1598-602. 2008
    ..Nanocrystalline silver has anti-inflammatory properties, prompting us to investigate its effect in experimental bladder inflammation...
  8. ncbi Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek--an oral multi-agent natural supplement
    T C Theoharides
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts 02111, USA
    Can J Urol 15:4410-4. 2008
    ....
  9. ncbi Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells
    M Vasiadi
    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Br J Dermatol 166:1349-52. 2012
    ..A peptide, neurotensin (NT), can trigger skin histamine release and augment the ability of CRH to increase skin vascular permeability...
  10. ncbi Urticaria pigmentosa associated with acute stress and lesional skin mast-cell expression of CRF-R1
    T C Theoharides
    Department of Pharmacology, Tufts University School of Medicine, Tufts Medical Center, Boston, MA 02111, USA
    Clin Exp Dermatol 34:e163-6. 2009
    ..This is the first documented report to our knowledge of UP worsening associated with acute stress, possibly through activation of skin mast-cell CRF-R1...
  11. ncbi Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells
    D Kempuraj
    Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA
    Br J Pharmacol 155:1076-84. 2008
    ..However, possible interactions between the two and the mechanism of such activations are largely unknown...
  12. ncbi The flavonoid luteolin inhibits niacin-induced flush
    D Papaliodis
    Laboratory for Molecular Immunopharmacology and Drug Discovery, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Tufts New England Medical Center, Boston, MA, USA
    Br J Pharmacol 153:1382-7. 2008
    ..We investigated whether niacin-induced flush in a rat model involves PGD2 and 5-HT, and the effect of certain flavonoids...
  13. ncbi Dermatitis characterized by mastocytosis at immunization sites in mast-cell-deficient W/Wv mice
    T C Theoharides
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass 02111
    Int Arch Allergy Immunol 102:352-61. 1993
    ..These findings may, therefore, help elucidate what regulates mast cell maturation/differentiation as well as their pathophysiology...
  14. ncbi Non-invasive assessment of blood-brain barrier (BBB) permeability using a gamma camera to detect 99technetium-gluceptate extravasation in rat brain
    P Esposito
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Brain Res Brain Res Protoc 8:143-9. 2001
    ..This method also allows for repeated experimentation on the same animal, since the half-life of 99Tc is only 6 h, and permits testing of potential inhibitors of BBB permeability...
  15. ncbi Mast cell involvement in interstitial cystitis: a review of human and experimental evidence
    T C Theoharides
    Department of Pharmacology, Tufts University School of Medicine and New England Medical Center, Boston, Massachusetts, USA
    Urology 57:47-55. 2001
    ..Activation of mast cells, irrespective of bladder location or degree of mastocytosis, is significant. Mast cell-derived vasoactive and proinflammatory molecules may contribute to the pathogenesis of IC...
  16. ncbi Ultrastructural evidence of brain mast cell activation without degranulation in monkey experimental allergic encephalomyelitis
    R Letourneau
    Department of Pharmacology, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    J Neuroimmunol 145:18-26. 2003
    ....
  17. ncbi A pilot open label study of Cystoprotek in interstitial cystitis
    T C Theoharides
    Departments of Pharmacology and Experimental Therapeutics, Biochemistry, and Internal Medicine, Tufts University School of Medicine, Boston, MA 02111, USA
    Int J Immunopathol Pharmacol 18:183-8. 2005
    ..2 (p < 0.05) and the Problem Index from 13.1 +/- 3.7 to 5.4 +/- 4.0 (p <0.05). These results are very promising and warrant a larger study that may permit further analyses with respect to other, especially atopic, comorbid diseases...
  18. ncbi Luteolin and thiosalicylate inhibit HgCl(2) and thimerosal-induced VEGF release from human mast cells
    S Asadi
    Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA
    Int J Immunopathol Pharmacol 23:1015-20. 2010
    ..Pretreatment for 10 min with the flavonoid luteolin (0.1 mM) before HgCl2 or thimerosal compeletly blocked their effect. Luteolin and methyl thiosalicylate may be useful in preventing mercury-induced toxicity...
  19. ncbi Inhibitory effect of quercetin on tryptase and interleukin-6 release, and histidine decarboxylase mRNA transcription by human mast cell-1 cell line
    D Kempuraj
    Pharmacology Department, Tufts University, Medical School, Boston, MA, USA
    Clin Exp Med 6:150-6. 2006
    ....
  20. ncbi Progesterone inhibits mast cell secretion
    M Vasiadi
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Tufts-New England Medical Center, Boston, MA, USA
    Int J Immunopathol Pharmacol 19:787-94. 2006
    ..These results suggest that mast cell secretion may be regulated by progesterone and may explain the reduced symptoms of certain inflammatory conditions during pregnancy...
  21. ncbi New agents for the medical treatment of interstitial cystitis
    T C Theoharides
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    Expert Opin Investig Drugs 10:521-46. 2001
    ....
  22. ncbi Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress
    W S Boucher
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA, USA
    J Urol 167:380-4. 2002
    ..Intravesical sodium hyaluronate may be a useful therapeutic option for interstitial cystitis, especially in patients with bladder mastocytosis who have symptom exacerbation with stress...
  23. ncbi Cloning and cellular localization of the rat mast cell 78-kDa protein phosphorylated in response to the mast cell "stabilizer" cromolyn
    T C Theoharides
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA, USA
    J Pharmacol Exp Ther 294:810-21. 2000
    ..It is hypothesized that conformational changes of moesin, regulated by phosphorylation/dephosphorylation, may lead to positional rearrangements with respect to the membrane/cytoskeleton that could possibly regulate mast cell secretion...
  24. ncbi Human umbilical cord blood-derived mast cells: a unique model for the study of neuro-immuno-endocrine interactions
    T C Theoharides
    Department of Laboratory of Molecular Immunopharmacology and Drug Discovery, Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA, USA
    Stem Cell Rev 2:143-54. 2006
    ..The recent use of live cell array, with its ability to study such interactions rapidly at the single-cell level, provides unique new opportunities for fast output screening of mast cell triggers and inhibitors...
  25. ncbi Expression of intercellular adhesion molecules in the bladder of patients with interstitial cystitis
    M Green
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Tufts-New England Medical Center, Boston, Massachusetts 02111, USA
    Urology 63:688-93. 2004
    ..CONCLUSIONS: These results showed that ICAM-1 is expressed in IC, with variable expression of the other markers studied, supporting the different degrees of bladder inflammation noted in patients with IC...
  26. ncbi Neuro-immuno-endocrine processes in vitiligo pathogenesis
    A Miniati
    Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine, Boston, MA, USA
    Int J Immunopathol Pharmacol 25:1-7. 2012
    ..Such interactions could serve the basis for further research, possibly leading to new treatments...
  27. ncbi Interstitial cystitis
    G R Sant
    Department of Urology, Tufts University School of Medicine, Boston, MA 02111, USA
    Curr Opin Urol 9:297-302. 1999
    ..Interstitial cystitis is a common disease among women and is frequently misdiagnosed as prostatitis and benign prostatic hyperplasia among men...
  28. ncbi A case series of a Luteolin formulation (neuroprotek&#63194;) in children with autism spectrum disorders
    T C Theoharides
    Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA
    Int J Immunopathol Pharmacol 25:317-23. 2012
    ..There were no adverse effects. Even though these results represent an uncontrolled open case series, they are encouraging because they suggest good tolerability and potential effectiveness...
  29. ncbi Do mast cells link obesity and asthma?
    N Sismanopoulos
    Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Molecular Physiology and Pharmacology, Tufts University School of Medicine, Boston, MA, USA
    Allergy 68:8-15. 2013
    ..Development of effective mast cell inhibitors may be a novel approach for the management of both asthma and obesity. Certain flavonoid combinations may be a promising new treatment approach...
  30. ncbi Acute stress shortens the time to onset of experimental allergic encephalomyelitis in SJL/J mice
    N Chandler
    Surgical Research, Tufts University School of Medicine, New England Medical Center, Boston, MA 02111, USA
    Brain Behav Immun 16:757-63. 2002
  31. ncbi A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis
    G R Sant
    New England Medical Center and Tufts University School of Medicine, Boston, MA, USA
    J Urol 170:810-5. 2003
    ..This trial demonstrated the feasibility of conducting a multicenter randomized clinical trial in IC using uniform procedures and outcomes. However, slow recruitment underscored the difficulties of evaluating commonly available IC drugs...
  32. ncbi Mast cell deficient W/Wv mice have lower serum IL-6 and less cardiac tissue necrosis than their normal littermates following myocardial ischemia-reperfusion
    K Bhattacharya
    Department of Cardiac Surgery, University of Glasgow, Glasgow, Scotland, UK
    Int J Immunopathol Pharmacol 20:69-74. 2007
    ..This finding entertains the prospect of developing prophylactic therapy--targeting selective inhibition of cardiac mast cell activation, in clinical situations involving medical or surgical myocardial revascularization...
  33. ncbi Interleukin-19 (IL-19) network revisited
    D Kempuraj
    Pharmacology Department, Tufts University, School of Medicine, Boston MA 02111, USA
    Int J Immunopathol Pharmacol 16:95-7. 2003
  34. ncbi Mast cell activation in children with migraine before and after training in self-regulation
    K Olness
    Department of Pediatrics, Case Western Reserve University, Rainbow Babies and Childrens Hospital, Cleveland, Ohio 44106, USA
    Headache 39:101-7. 1999
    ..There was no relationship between successful practice and sex or age of the child. These results suggest that stress may activate mast cells which could be involved in the pathophysiology of migraine...
  35. ncbi Mesenteric traction syndrome or gut in distress
    D V Avgerinos
    Int J Immunopathol Pharmacol 18:195-9. 2005
    ..Some evidence points to the involvement of mast cell derived vasoactive mediators and suggests possible pharmacologic management...
  36. ncbi Theophylline as "add-on" therapy in patients with delayed pressure urticaria: a prospective self-controlled study
    D Kalogeromitros
    Division of Allergy and Clinical Immunology, Attikon Hospital, University of Athens School of Medicine, Athens, Greece
    Int J Immunopathol Pharmacol 18:595-602. 2005
    ..A double-blind study, accompanied by serum histamine and tryptase levels, should be in order...
  37. ncbi Inhibitory effect of retinoic acid on proliferation, maturation and tryptase level in human leukemic mast cells (HMC-1)
    M G Alexandrakis
    Department of Hematology, University of Crete School of Medicine, University Hospital of Herakleion, Crete, Greece
    Int J Immunopathol Pharmacol 16:43-7. 2003
    ..These results indicate that ATRA significantly inhibits both proliferation and growth as shown by the decreased intracellular tryptase levels in HMC-1. ATRA may be a useful agent in the treatment of mast cell proliferative disorders...
  38. ncbi A quercetin containing supplement reduces niacin-induced flush in humans
    D Kalogeromitros
    Allergy Clinical Research Center, Allergy Section, Attikon Hospital, University of Athens Medical School, Athens, Greece
    Int J Immunopathol Pharmacol 21:509-14. 2008
    ..5+/-0.58 and lasted only for 1.68+/-0.70 hours. Quercetin also inhibited methylnicotinate-induced human mast cell PGD2 release. These preliminary results suggest that quercetin could reduce niacin-induced "flush" in humans...
  39. ncbi Immunological activation of human umbilical cord blood mast cells induces tryptase secretion and interleukin-6, and histidine decarboxilase mRNA gene expression
    M L Castellani
    Immunology Division, Medical School, University of Chieti Pescara, Italy
    Pharmacol Res 55:57-63. 2007
    ..Moreover, with these data we confirm the immunoregulatory and inflammatory function of mast cells...
  40. ncbi Allergic inflammation and adipocytokines
    T C Theoharides
    Int J Immunopathol Pharmacol 21:1-4. 2008
  41. ncbi A pilot, open label, clinical trial using hydroxyzine in multiple sclerosis
    L Logothetis
    Department of Neurology, Aristotle University, AHEPA Hospital, Thessaloniki, Greece
    Int J Immunopathol Pharmacol 18:771-8. 2005
    ..Hydroxyzine could be used as an adjuvant in MS, but the small number of patients enrolled and the short duration of the study precludes any definitive conclusions. A double-blind, placebo-controlled study is warranted...
  42. ncbi Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32)
    P Conti
    Immunology Division, Department of Oncology and Neuroscience, University of Chieti, Via dei Vestini, 66100 Chieti, Italy
    Autoimmun Rev 6:131-7. 2007
    ..Discovery of this supplementary inflammatory cytokine further complicates the network of inflammation...
  43. ncbi Localization and activity of iNOS in normal human lung tissue and lung cancer tissue
    L Speranza
    Department of Human Dynamics, University of Chieti, Via dei Vestini, 66100 Chieti, Italy
    Int J Biol Markers 22:226-31. 2007
    ....
  44. ncbi Anti-chemokine therapy for inflammatory diseases
    M L Castellani
    Department of Internal Medicine and Science of Ageing, University of Chieti, Italy
    Int J Immunopathol Pharmacol 20:447-53. 2007
    ..RANTES and MCP-1 may represent targets for diagnostic procedures and therapeutic intervention, and may be useful as a prognostic factor in the above diseases...
  45. ncbi Delayed inflammation in rat meninges: implications for migraine pathophysiology
    U Reuter
    Stroke and Neurovascular Regulation Laboratory, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Brain 124:2490-502. 2001
    ....